Glomerulonephritis membranous

2 trials 2 recruiting MedDRA PT
2 Registered trials
2 Recruiting
2 Unique sponsors
2 Unique IMPs
1 Commercial trials
Drug classes (ATC)
— ATC code not specified 1
A Gastroenterology (ATC A) 1
Mechanism of action (INN-stem analysis)
Receptor fusion protein 1 substance
SGLT2 inhibitor 1 substance
Phase II/III: 1 Phase II: 1

Filter these 2 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 2 trials

Phase II/III

1 trial
  • Centre Hospitalier Universitaire De Nantes Academic
    DAPAGLIFLOZIN
    2023-507658-34-00 1 country 2025 n=20
    Recruiting

Phase II

1 trial
  • Vera Therapeutics Inc. Commercial
    ATACICEPT
    2024-518465-10-00 6 countries 2025 n=124 Orphan
    Recruiting
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Vera Therapeutics Inc. Commercial 1 Phase II 1
Centre Hospitalier Universitaire De Nantes Academic 1 Phase II/III 1
New trials by year
2025
2
← All indication landscapes